Boone Capital Management LLC holds a focused book of 13 stocks worth $326.4M as of Q1 2026 (disclosed May 15, 2026, a ~45-day 13F lag). This quarter they opened Teleflex Inc and trimmed Medtronic PLC. Their largest long position is Mirum Pharmaceuticals Inc at 12% of the equity book. Cloning the disclosed picks since 2023 would be +37% (+9.6%/yr). That is a simulation of the disclosed long book, not audited returns.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1882053/holdings"
Use Arkolith to show BOONE CAPITAL MANAGEMENT LLC's latest holdings, largest changes, and filing provenance.
The reported book (valued from quarter-end) returned +47.6%, a 10.2-point gap that is the cost of the ~45-day 13F disclosure lag a real follower can't avoid.
Growth of $10,000 cloning Boone Capital Management LLC's disclosed long 13F book, rebalanced on each filing date (so it reflects the ~45-day reporting lag, no look-ahead), total-return basis (dividends reinvested), derived from end-of-day prices. “Their reported book” values the same picks from quarter-end, before they were public. S&P 500 is SPY total return over the same window. Excludes shorts, cash, options and non-13F holdings. Not investment advice.
Top-heavy: focused book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
100% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Other tracked managers holding the same core names as Boone Capital Management LLC
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| VANGUARD GROUP INC | 18 / 13 | $56.9B |
| BlackRock, Inc. | 18 / 13 | $43.7B |
| VANGUARD CAPITAL MANAGEMENT LLC | 18 / 13 | $39.7B |
| STATE STREET CORP | 18 / 13 | $23.6B |
| JPMORGAN CHASE & CO | 18 / 13 | $15.6B |
| FMR LLC | 18 / 13 | $15.3B |
| PRICE T ROWE ASSOCIATES INC /MD/ | 18 / 13 | $11.7B |
| BANK OF AMERICA CORP /DE/ | 18 / 13 | $10.6B |
Ranked by how many of Boone Capital Management LLC's top 13 disclosed names each fund also holds: a cross-fund conviction signal from the latest 13F of every tracked manager.
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Mirum Pharmaceuticals Inc COM | $38.9M | 421.2K | 11.9% | —Held | |
| 2 | Ionis Pharmaceuticals Inc COM | $37.6M | 500.5K | 11.5% | ▲+20% Added · +83K sh | |
| 3 | The Cigna Group COM | $36.7M | 137.5K | 11.2% | ▲+43% Added · +41K sh | |
| 4 | Medtronic PLC SHS | $34.5M | 398.1K | 10.6% | ▼−7.2% Reduced · −31K sh | |
| 5 | Teleflex Incorporated COM | $33.3M | 278.8K | 10.2% | ▲New New position | |
| 6 | Biomarin Pharmaceutical Inc COM | $30.9M | 547.9K | 9.5% | ▲+33% Added · +136K sh | |
| 7 | Guardian Pharmacy Svcs Inc CL A | $23.8M | 631.2K | 7.3% | ▲New New position | |
| 8 | AstraZeneca PLC ORD | $21.7M | 110.1K | 6.7% | ▲New New position | |
| 9 | Unitedhealth Group Inc COM | $21.4M | 79.2K | 6.6% | ▲+28% Added · +17K sh | |
| 10 | Bridgebio Pharma Inc COM | $17.0M | 228.8K | 5.2% | ▲+24% Added · +44K sh | |
| 11 | Avanos Med Inc COM | $16.6M | 1.18M | 5.1% | ▲New New position | |
| 12 | Kodiak Sciences Inc COM | $10.7M | 281.3K | 3.3% | ▼−44% Reduced · −222K sh | |
| 13 | Tenax Therapeutics Inc COM NEW | $3.2M | 200.0K | 1.0% | ▲New New position |
As-of date vs the date the SEC received each filing
| Quarter | As of | Filed | Positions | Value | Form |
|---|---|---|---|---|---|
| Q1 2026 | Mar 31, 2026 | May 15, 2026 | 13 | $326.4M | 13F-HR |
| Q4 2025 | Dec 31, 2025 | Feb 17, 2026 | 15 | $318.6M | 13F-HR |
| Q3 2025 | Sep 30, 2025 | Nov 14, 2025 | 16 | $305.0M | 13F-HR |
| Q2 2025 | Jun 30, 2025 | Aug 14, 2025 | 11 | $233.2M | 13F-HR |
| Q1 2025 | Mar 31, 2025 | May 15, 2025 | 12 | $293.8M | 13F-HR |
| Q4 2024 | Dec 31, 2024 | Feb 14, 2025 | 13 | $296.5M | 13F-HR |
| Q3 2024 | Sep 30, 2024 | Nov 14, 2024 | 17 | $385.8M | 13F-HR |
| Q2 2024 | Jun 30, 2024 | Aug 14, 2024 | 19 | $383.4M | 13F-HR |
| Q1 2024 | Mar 31, 2024 | May 15, 2024 | 21 | $494.4M | 13F-HR |
| Q4 2023 | Dec 31, 2023 | Feb 14, 2024 | 21 | $428.4M | 13F-HR |
| Q3 2023 | Sep 30, 2023 | Nov 14, 2023 | 13 | $317.0M | 13F-HR |
| Q2 2023 | Jun 30, 2023 | Aug 14, 2023 | 13 | $278.6M | 13F-HR |
| Q1 2023 | Mar 31, 2023 | May 15, 2023 | 12 | $213.6M | 13F-HR |
| Q4 2022 | Dec 31, 2022 | Feb 14, 2023 | 17 | $194.9M | 13F-HR |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly ~45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. The performance line is a simulation of the disclosed long book, not an audited return.